Health Catalyst Inc. (HCAT)
Health Catalyst Investors Approve Directors, Pay; Board Declassification Fails
Health Catalyst NASDAQ: HCAT stockholders approved three of four proposals presented at the company's 2026 annual meeting, including the election of two directors, ratification of the company's auditor and an advisory vote on executive compensation. A proposal to phase out the company's classified board structure did not receive the required level of support.
Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript
Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript
Health Catalyst Q1 Earnings Call Highlights
Health Catalyst NASDAQ: HCAT reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company's operating model, reducing costs and shifting the business further toward technology-led growth.
Health Catalyst (HCAT) Q1 Earnings and Revenues Surpass Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.01 per share a year ago.
Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Evaluate the expected performance of Health Catalyst (HCAT) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Hold” by Brokerages
Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average recommendation of "Hold" from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The
Health Catalyst (HCAT) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Health Catalyst (HCAT) Lags Q4 Earnings Estimates
Health Catalyst (HCAT) came out with quarterly earnings of $0.08 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.04 per share a year ago.
Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Transcript
Health Catalyst, Inc. (HCAT) Q4 2025 Earnings Call Transcript
Health Catalyst (HCAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Health Catalyst (HCAT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Gear Up for Health Catalyst (HCAT) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top-and-bottom-line estimates for Health Catalyst (HCAT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.
